Psychedelics research lacks sufficient evidence for ADHD treatment

Recent systematic reviews indicate that current scientific evidence is insufficient to support the use of psychedelics as a treatment for ADHD. While there is growing public interest in microdosing for managing attention, impulsivity, and emotional regulation, researchers found only five studies meeting the criteria for scientific evaluation regarding ADHD.

These studies included observational research on microdosing, a randomized clinical trial using low doses of LSD, and a pilot study on ritual ayahuasca use. Although participants in observational studies reported short-term improvements in mood and concentration, researchers noted that these study designs cannot definitively prove the substances caused the improvements.

Broadly, research into psilocybin and other psychedelics has focused on depression, anxiety, and PTSD. While full-dose interventions combined with psychotherapy have shown promise in treating mental health disorders, experts warn that the results from supervised, perceptible-dose therapy cannot be automatically applied to modern microdosing, which typically involves sub-perceptual doses taken outside of clinical supervision.